Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression

Journal of Translational Medicine - Tập 1 - Trang 1-11 - 2003
Dimitrios Panutsopulos1, Alexandros Zafiropoulos1, Elias Krambovitis2, George E Kochiadakis3, Nikos E Igoumenidis3, Demetrios A Spandidos1
1Laboratory of Virology, Medical School, University of Crete, Heraklion, Greece
2Department of Applied Biochemistry & Immunology, Institute of Molecular Biology & Biotechnology, Vassilika Vouton, Heraklion, Greece
3Cardiology Department, University Hospital of Heraklion, Crete, Greece

Tóm tắt

Macrophages can produce vascular endothelial growth factor (VEGF) in response to hypoxia, transforming growth factor β1 (TGF-β1), angiotensin II, basic fibroblast growth factor (bFGF), and interleukin-1. These factors have been found in the serum of coronary artery disease (CAD) patients as well as in atherosclerotic lesions. The aim of the present study was to test the hypothesis that the expression of VEGF, TGF-β1 and bFGF in peripheral monocytes and lymphocytes is related to CAD. Human Mononuclear cells and lymphocytes from peripheral blood were isolated from 53 donors undergoing angiography. Seventeen were found to be healthy and 36 were diagnosed with CAD. The respective mRNAs were extracted and quantified. The statistical analysis revealed a significant increase of the basal level expression for macrophage VEGF and bFGF in the CAD SA (stable angina) patient group compared to the noCAD (control) (p = 0.041 and p = 0.022 respectively) and CAD UA (unstable angina) (p = 0.024 and p = 0.005 respectively) groups, which was highly dependent on the diabetic status of the population. Furthermore, we demonstrated with an in vitro cell culture model that the levels of VEGF and bFGF in monocytes of healthy donors are not affected by short term exposure to increased glucose levels (usually observed in the diabetic patients) and/or statin. Our findings display a statistically significant association of the increased VEGF and bFGF levels in peripheral monocytes, with stable angina and diabetes in coronary artery disease. The results give new insight to CAD and the impaired collateral vessel formation in diabetics.

Từ khóa


Tài liệu tham khảo

Lusis AJ: Atherosclerosis. Nature. 2000, 407: 233-241. 10.1038/35025203.

Kruth HS: Macrophage foam cells and atherosclerosis. Front Biosci. 2001, 6: D429-55.

Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993, 362: 801-809. 10.1038/362801a0.

O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, Schwartz SM: Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol. 1994, 145: 883-894.

Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W: Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 1998, 101: 40-50.

Piek JJ, van Liebergen RA, Koch KT, Peters RJ, David GK: Clinical, angiographic and hemodynamic predictors of recruitable collateral flow assessed during balloon angioplasty coronary occlusion. J Am Coll Cardiol. 1997, 29: 275-282.

Sampath R, Kukielka GL, Smith CW, Eskin SG, McIntire LV: Shear stress-mediated changes in the expression of leukocyte adhesion receptors on human umbilical vein endothelial cells in vitro. Ann Biomed Eng. 1995, 23: 247-256.

Waltenberger J: Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res. 2001, 49: 554-560. 10.1016/S0008-6363(00)00228-5.

Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP: Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation. 1999, 100: 547-552.

Waltenberger J, Lange J, Kranz A: Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation. 2000, 102: 185-190.

Ferrara N, Bunting S: Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens. 1996, 5: 35-44.

Williams B, Baker AQ, Gallacher B, Lodwick D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension. 1995, 25: 913-917.

Havel RJ, Rapaport E: Management of primary hyperlipidemia. N Engl J Med. 1995, 332: 1491-1498. 10.1056/NEJM199506013322207.

MAAS_Investigators: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994, 344: 633-638. 10.1016/S0140-6736(94)92082-6.

Zhu BQ, Sievers RE, Sun YP, Isenberg WM, Parmley WW: Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol. 1992, 19: 246-255.

Rothe G, Herr AS, Stohr J, Abletshauser C, Weidinger G, Schmitz G: A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis. 1999, 144: 251-261. 10.1016/S0021-9150(99)00061-1.

Zafiropoulos A, Baritaki S, Vlata Z, Spandidos DA, Krambovitis E: Dys-regulation of effector CD4+ T cell function by the V3 domain of the HIV-1 gp120 during antigen presentation. Biochem Biophys Res Commun. 2001, 284: 875-879. 10.1006/bbrc.2001.5046.

Zar JH: Biostatistical Analysis. 1999, Prentice Hall International, 145-155. 4

Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T, Asch AS: A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med. 2001, 7: 840-846. 10.1038/89969.

Kumar S, West D, Shahabuddin S, Arnold F, Haboubi N, Reid H, Carr T: Angiogenesis factor from human myocardial infarcts. Lancet. 1983, 2: 364-368. 10.1016/S0140-6736(83)90343-4.

Casscells W, Speir E, Sasse J, Klagsbrun M, Allen P, Lee M, Calvo B, Chiba M, Haggroth L, Folkman J, et al.: Isolation, characterization, and localization of heparin-binding growth factors in the heart. J Clin Invest. 1990, 85: 433-441.

Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K: Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998, 98: 2108-2116.

Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, Symes J, Isner JM: Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol. 1997, 150: 1673-1685.

Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996, 87: 3336-3343.

Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY: Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001, 276: 7614-7620. 10.1074/jbc.M009705200.

Marumo T, Schini-Kerth VB, Busse R: Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes. 1999, 48: 1131-1137.

Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N: Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels. 2000, 15: 105-111.

Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N: Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000, 93: 168-174. 10.1159/000007022.

Ogawa H, Suefuji H, Soejima H, Nishiyama K, Misumi K, Takazoe K, Miyamoto S, Kajiwara I, Sumida H, Sakamoto T, Yoshimura M, Kugiyama K, Yasue H, Matsuo K: Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology. 2000, 93: 93-99. 10.1159/000007008.

Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ: Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol. 1996, 80: 363-366.

Blann AD, Belgore FM, Constans J, Conri C, Lip GY: Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol. 2001, 87: 1160-1163. 10.1016/S0002-9149(01)01486-2.

Belgore FM, Blann AD, Lip GY: Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci. 2001, 100: 567-575. 10.1042/CS20000234.

Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY: Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci. 2002, 102: 187-194. 10.1042/CS20010178.

Dantz D, Bewersdorf J, Fruehwald-Schultes B, Kern W, Jelkmann W, Born J, Fehm HL, Peters A: Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia. J Clin Endocrinol Metab. 2002, 87: 835-840. 10.1210/jc.87.2.835.

Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999, 99: 2239-2242.

Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W, Ishibashi M, Hiasa Ki K, Ichiki T, Shibuya M, Takeshita A: Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation. 2002, 105: 1110-1115. 10.1161/hc0902.104718.

Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996, 271: 17629-17634. 10.1074/jbc.271.30.17629.

Thông tin
Thông tin xuất bản

Journal of Translational Medicine

Tập 1

1-11

Thông tin tác giả